

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)*

Sana Biotechnology, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☐ Rule 13d-1(c)
- ☒ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

- 1

Names of Reporting Persons

ARCH Venture Fund IX, L.P.

Check the appropriate box if a member of a Group (see instructions)
- 2

☐ (a)

☐ (b)
- 3

Sec Use Only

Citizenship or Place of Organization
- 4

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
	0.00	
		Shared Voting Power
	6	
	45,860,681.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	45,860,681.00	
	Aggregate Amount Beneficially Owned by Each Reporting Person	
9	45,860,681.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	☐	
11	Percent of class represented by amount in row (9)	
	15.3 %	
12	Type of Reporting Person (See Instructions)	
	PN	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	
	ARCH Venture Fund IX Overage, L.P.	
	Check the appropriate box if a member of a Group (see instructions)	
2	☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization	
	DELAWARE	
	Sole Voting Power	
	5	
	0.00	
Number of Shares Beneficially Owned by Each Reporting Person With:	6	Shared Voting Power
	45,860,681.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	45,860,681.00	
	Aggregate Amount Beneficially Owned by Each Reporting Person	
9	45,860,681.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	☐	

11	Percent of class represented by amount in row (9)
	15.3 %
	Type of Reporting Person (See Instructions)
12	PN

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	ARCH Venture Fund X, L.P.
	Check the appropriate box if a member of a Group (see instructions)

2	☐ (a)
	☐ (b)

3	Sec Use Only
	Citizenship or Place of Organization

4	DELAWARE
---	----------

	Sole Voting Power
5	0.00
	Shared Voting Power
6	45,860,681.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive
8	Power
	45,860,681.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

	Aggregate Amount Beneficially Owned by Each Reporting Person
9	45,860,681.00
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10	☐
----	--------------------------

	Percent of class represented by amount in row (9)
11	15.3 %
	Type of Reporting Person (See Instructions)
12	PN

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	ARCH Venture Fund X Overage, L.P.
2	Check the appropriate box if a member of a Group (see instructions)

☐ (a)
☐ (b)

3 Sec Use Only
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

Beneficially
Owned by

45,860,681.00

Each

Sole Dispositive Power

7

Reporting

0.00

Person

Shared Dispositive

With:

Power

8

45,860,681.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

45,860,681.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

☐

Percent of class represented by amount in row (9)

11

15.3 %

Type of Reporting Person (See Instructions)

12

PN

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

ARCH Venture Partners IX, L.P.

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)
☐ (b)

3 Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of
Shares

Sole Voting Power

5

Beneficially
Owned by

0.00

Each

Shared Voting Power

6

Reporting
Person

45,860,681.00

With:

Sole Dispositive Power

7

0.00

8 Shared Dispositive
Power

	45,860,681.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	45,860,681.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	15.3 %
12	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	ARCH Venture Partners IX Overage, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	45,860,681.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	45,860,681.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	45,860,681.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	15.3 %
12	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	ARCH Venture Partners X Overage, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
Number of	Shared Voting Power
Shares	6
Beneficially	45,860,681.00
Owned by	Sole Dispositive Power
Each	7
Reporting	0.00
Person	Shared Dispositive
With:	8 Power
	45,860,681.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	45,860,681.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	15.3 %
12	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13G**CUSIP No.**

1	Names of Reporting Persons
	ARCH Venture Partners X, L.P.
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
Number of	Sole Voting Power
Shares	5
Beneficially	0.00
Owned by	6 Shared Voting Power
Each	

Reporting Person	45,860,681.00
With:	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	45,860,681.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	45,860,681.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	15.3 %
12	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	ARCH Venture Partners IX, LLC
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
	Shared Voting Power
6	45,860,681.00
	Sole Dispositive Power
7	0.00
	Shared Dispositive Power
8	45,860,681.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	45,860,681.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	15.3 %
12	Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	ARCH Venture Partners X, LLC
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	0.00
Number of	Shared Voting Power
Shares	6
Beneficially	45,860,681.00
Owned by	Sole Dispositive Power
Each	7
Reporting	0.00
Person	Shared Dispositive
With:	8 Power
	45,860,681.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	45,860,681.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	15.3 %
12	Type of Reporting Person (See Instructions)
	OO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	Keith Crandell
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only

4 Citizenship or Place of Organization

UNITED STATES

 Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

45,860,681.00

Sole Dispositive Power

7

0.00

Shared Dispositive
Power

8

45,860,681.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

45,860,681.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10



Percent of class represented by amount in row (9)

11

15.3 %

Type of Reporting Person (See Instructions)

12

IN

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Clinton Bybee

Check the appropriate box if a member of a Group (see instructions)

2



(a)



(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

 Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

45,860,681.00

Sole Dispositive Power

7

0.00

Shared Dispositive
Power

8

45,860,681.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

45,860,681.00

10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	15.3 %
12	Type of Reporting Person (See Instructions)
	IN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
	Robert Nelsen
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	UNITED STATES
	Sole Voting Power
5	312,444.00
	Shared Voting Power
6	45,860,681.00
	Sole Dispositive Power
7	312,444.00
	Shared Dispositive
8	Power
	45,860,681.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

9	Aggregate Amount Beneficially Owned by Each Reporting Person
	46,173,125.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	☐
11	Percent of class represented by amount in row (9)
	15.4 %
12	Type of Reporting Person (See Instructions)
	IN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons
---	----------------------------

Steven Gillis
Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)
☐ (b)

3

Sec Use Only
Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

45,860,681.00

Sole Dispositive Power

7

0.00

Shared Dispositive
Power

8

45,860,681.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

45,860,681.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

☐

Percent of class represented by amount in row (9)

11

15.3 %

Type of Reporting Person (See Instructions)

12

IN

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Kristina Burow

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)
☐ (b)

3

Sec Use Only
Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

45,860,681.00

Sole Dispositive Power

7

0.00

8 Shared Dispositive
Power

45,860,681.00

Aggregate Amount Beneficially Owned by Each Reporting Person

45,860,681.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)



Percent of class represented by amount in row (9)

15.3 %

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Sana Biotechnology, Inc.

Address of issuer's principal executive offices:

(b)

188 East Blaine Street, Suite 350, Seattle, WA 98102

Item 2.

Name of person filing:

ARCH Venture Fund IX, L.P. ("AVF IX"); ARCH Venture Partners IX, L.P. ("AVP IX LP"); ARCH Venture Partners IX, LLC ("AVP IX LLC"); ARCH Venture Fund IX Overage, L.P. ("AVF IX Overage"); ARCH Venture Partners IX Overage, L.P. ("AVP IX Overage GP"); ARCH Venture Fund X, L.P. ("AVF X"); ARCH Venture Partners X, L.P. ("AVP X LP"); ARCH Venture Fund X Overage, L.P. ("AVF X Overage"); ARCH Venture Partners X Overage, L.P. ("AVP X Overage GP"); ARCH Venture Partners X, LLC ("AVP X LLC"); (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director"), and Steven Gillis ("Gillis") and Kristina Burow ("Burow"), along with Nelsen and Crandell, collectively the "Investment Committee"; individually "Committee Members". The Reporting Entities, Managing Directors and the Investment Committee Members collectively are referred to as the "Reporting Persons". The Reporting Persons are filing this report with respect to shares of Common Stock, par value \$0.0001 per share (the "Common Stock") of Sana Biotechnology, Inc. (the "Issuer").

(a)

Address or principal business office or, if none, residence:

(b)

8755 W. Higgins Road, Suite 1025, Chicago, IL 60631

Citizenship:

(c)

Each of AVF IX, AVP IX LP, AVF IX Overage, AVP IX Overage GP, AVF X, AVP X LP, AVF X Overage and AVP X Overage GP are limited partnerships organized under the laws of the State of Delaware. AVP IX LLC and AVP X LLC are each a limited liability company organized under the laws of the State of Delaware. Each Managing Director and Committee Member is a US citizen.

Title of class of securities:

(d)

Common Stock, par value \$0.0001 per share

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

- AVF IX is the record owner of 10,667,387 shares of Common Stock (the "AVF IX Shares") as of June 30, 2026. AVP IX LP, as the sole general partner of AVF IX, may be deemed to beneficially own the AVF IX Shares. AVF IX Overage is the record owner of 10,301,250 shares of Common Stock (the "AVF IX Overage Shares") as of June 30, 2026. AVP IX Overage GP, as the sole general partner of AVF IX Overage, may be deemed to beneficially own the AVF IX Overage Shares, combined with AVF IX Shares (the "IX Record Shares"). AVF X is the record owner of 12,446,022 shares of Common Stock (the "AVF X Shares") as of June 30, 2026. AVP X LP, as the sole general partner of AVF X, may be deemed to beneficially own the AVF X Shares. AVF X Overage is the record owner of 12,446,022 shares of Common Stock (the "AVF X Overage Shares") as of June 30, 2026. AVP X Overage GP, as the sole general partner of AVF X Overage, may be deemed to beneficially own the AVF X Overage Shares, combined with AVF X Shares (the "X Record Shares"). AVP IX LLC, as the sole general partner of AVP IX LP and AVP IX Overage GP, may be deemed to beneficially own the IX Record Shares. As managing directors of AVP IX LLC, each Managing Director may also be deemed to share the power to direct the disposition and vote of the IX Record Shares. AVP X LLC, as the sole general partner of AVP X LP and AVP X Overage GP, may be deemed to beneficially own the X Record Shares. As Investment Committee Members of AVP X LLC, each Committee Member may also be deemed to share the power to direct the disposition and vote of the X Record Shares. In addition, as of June 30, 2026, Nelsen is a holder of vested options to purchase 298,591 shares of Common Stock (the "Vested Option Shares") and 1,353 fully vested restricted stock units ("RSUs") and Enzo Family Trust of 2015, the beneficiaries of which are members of Nelsen's family, holds 12,500 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.
- Percent of class:

- (b) The information required by Item 4(b) is incorporated by reference to Row 11 of the cover pages hereto. The percentages set forth on the cover pages for each Reporting Person (other than Nelsen) are based upon 299,360,637 shares of Common Stock outstanding as of August 3, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2026, and, in the case of Nelsen, assumes the exercise of the Vested Option Shares. %
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote:

See row 5 of the cover pages.
 - (ii) Shared power to vote or to direct the vote:

See row 6 of the cover pages.
 - (iii) Sole power to dispose or to direct the disposition of:

See row 7 of the cover pages.
 - (iv) Shared power to dispose or to direct the disposition of:

See row 8 of the cover pages.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ARCH Venture Fund IX, L.P.

Signature: /s/ ARCH Venture Partners IX, L.P.

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ Mark McDonnell*

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell, Managing Director

Date: 08/14/2026

ARCH Venture Fund IX Overage, L.P.

Signature: /s/ ARCH Venture Partners IX Overage, L.P.

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ ARCH Venture Partners IX, LLC

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell, Managing Director

Date: 08/14/2026

ARCH Venture Fund X, L.P.

Signature: /s/ ARCH Venture Partners X, L.P.

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ ARCH Venture Partners X, LLC

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell, Managing Director

Date: 08/14/2026

ARCH Venture Fund X Overage, L.P.

Signature: /s/ ARCH Venture Partners X Overage, L.P.

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ ARCH Venture Partners X, LLC

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith

Crandell, Managing Director

Date: 08/14/2026

ARCH Venture Partners IX, L.P.

Signature: /s/ ARCH Venture Partners IX, LLC

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell, Managing Director

Date: 08/14/2026

ARCH Venture Partners IX Overage, L.P.

Signature: /s/ ARCH Venture Partners IX, LLC

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell, Managing Director

Date: 08/14/2026

ARCH Venture Partners X Overage, L.P.

Signature: /s/ ARCH Venture Partners X, LLC

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell, Managing Director

Date: 08/14/2026

ARCH Venture Partners X, L.P.

Signature: /s/ ARCH Venture Partners X, LLC

Name/Title: its General Partner

Date: 08/14/2026

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell, Managing Director

Date: 08/14/2026

ARCH Venture Partners IX, LLC

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell, Managing Director

Date: 08/14/2026

ARCH Venture Partners X, LLC

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell, Managing Director

Date: 08/14/2026

Keith Crandell

Signature: /s/ Mark McDonnell

Name/Title: Mark McDonnell as Attorney-in-Fact for Keith
Crandell

Date: 08/14/2026

Clinton Bybee

Signature: /s/ Mark McDonnell
Name/Title: Mark McDonnell as Attorney-in-Fact for Clinton Bybee
Date: 08/14/2026

Robert Nelsen

Signature: /s/ Mark McDonnell
Name/Title: Mark McDonnell as Attorney-in-Fact for Robert Nelsen
Date: 08/14/2026

Steven Gillis

Signature: /s/ Mark McDonnell
Name/Title: Mark McDonnell as Attorney-in-Fact for Steven Gillis
Date: 08/14/2026

Kristina Burow

Signature: /s/ Mark McDonnell
Name/Title: Mark McDonnell as Attorney-in-Fact for Kristina Burow
Date: 08/14/2026

Comments accompanying signature: * This Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24.0 and Exhibit 24.1 to the Form 3 relating to the beneficial ownership of shares of Sana Biotechnology, Inc. by certain of the Reporting Persons filed with the Securities and Exchange Commission on February 3, 2021 and incorporated herein in its entirety by reference and Powers of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Gossamer Bio, Inc. by certain of the Reporting Persons filed with the Securities and Exchange Commission on February 7, 2019 and incorporated herein in its entirety by reference.